February 2021

Promising results for lenvatinib in combination with pembrolizumab or everolimus in 1L advanced renal cell carcinoma

The results of the phase 3 CLEAR-study in 1L treatment of patients with advanced renal cell carcinoma show that lenvatinib in combination with pembrolizumab or everolimus improve progression-free survival and response rate compared to sunitinib, whereas the combination of lenvatinib and pembrolizumab also significantly improves survival.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Register
Already a user? Login

Back to top

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Preferences

Preference cookies are used to store user preferences to provide content that is customized and convenient for the users, like the language of the website or the location of the visitor.

Cookie	Duration	Description
_gat_UA-43794127-5	1 minute	This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.

Promising results for lenvatinib in combination with pembrolizumab or everolimus in 1L advanced renal cell carcinoma

Get access to the article

Relateret indhold

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

ICI-based treatment as first-line therapy improves outcomes in patients with nccRCC